A CD22-targeting CAR with a 4–1BB costimulatory domain, granted FDA breakthrough therapy designation based on its efficacy in children and young adults with relapsed/refractory B-ALL Fry et al. (2018), was used in 74 mice. This evidence concerns the gene CD22 and acute lymphoblastic leukemia.